Verification Code :
Please do the math below and enter the answer in the area below

Rezulin Diabetic drug

Defective Products Lawyers

If you need a lawyer’s assistance  please contact  our Indiana Defective Products Lawyer

Indiana Defective Products LawyerRezulin® (also known as Noscal and troglitazone) was manufactured by the Warner Lambert Company (which was later purchased by Rezulin Lawyers Pfizer Inc.).  It was developed to treat Type 2 or adult-onset diabetes and was approved for that use in early 1997.  Rezulin works by lowering blood sugar levels by helping the body better respond to insulin (it was not a replacement therapy for insulin).  Insulin, assisted by Rezulin, removes sugar from the blood and helps transport it to the cells for energy production.  Improperly treated, diabetes can result in heart and kidney failure and blindness.

The FDA approved Rezulin® on a ‘fast track’ basis despite links to several liver-related deaths.  To obtain this expedited approval, it has been alleged that Warner Lambert misled the FDA by inaccurately reporting the risks of Rezulin®.  If this is true, and the manufacturer intentionally misrepresented the benign nature of the drug’s risks, there would be a violation of federal law which prohibits the deliberate concealing of important facts related to a drug’s safety.  There is also concern that Warner Lambert hid facts related to a Rezulin-related death

The greatest concern with Rezulin® use is liver damage and failure.  There are few visible symptoms of early stage liver damage/disease and there is no pain associated with the disease at early stages.  At more advanced stages, yellowing of the skin and eyes will occur.  Nausea will also ensue.  Ultimately, the liver may fail to function properly, if at all.  When the liver ceases to function, the result is death unless there is a successful liver transplant.

Early in its use, the FDA required the manufacturer to replace warning labels so that consumers could be made aware of discovered harmful impacts.  The most important label change was related to the potential for liver damage.  An FDA Advisory Committee also recommended (not required) that Rezulin® use be prohibited for persons whose diabetes could be properly regulated with insulin or less harmful drugs.  Eventually, the FDA sought to remove Rezulin from the market, however, for a little more than two years Warner Lambert prevented the withdrawal.  Rezulin was ultimately withdrawn from the United States market on March 21, 2000.  Specifically, the recall cited unacceptable risk of use to diabetes patients from liver damage or failure.  Before the drug was recalled, Warner Lambert had generated approximately $2.0 billion in revenue but at the cost of more than 375 Rezulin-related deaths.

Troglitazone, the active ingredient in Rezulin®, has not been widely studied in pregnant women.  It is not known therefore, whether infants were exposed to the drug during breast-feeding.  Studies have been conducted only in adult patients, including some elderly subjects.  Thus, there is no specific data regarding harm to fetuses, infants, or children from Rezulin use.

Rezulin® use may cause or exacerbate many health-related conditions and/or symptoms:


  • Abdominal or stomach pain
  • Appetite loss
  • Back pain
  • Death
  • Diarrhea
  • Dizziness
  • Fluid retention
  • Headache
  • Infection
  • Liver disease
  • Nausea or vomiting
  • Pain, generalized
  • Sore throat
  • Stuffy nose
  • Swelling of feet or lower legs
  • Tiredness, weariness or weakness
  • Urination, painful or increased frequency
  • Urination, discoloration ( darkening)
  • Yellowing of the eyes or skin


Defective Products Lawyers

If you need a lawyer’s assistance  please contact our Indiana Defective Products Lawyer


2124 East Hanna Ave, Indianapolis, Indiana 46227-3314
(800) 486-4450, (317) 780-6610
Fax: (317) 780-6620
“Over 50 Years of Combined Trial & Settlement Experience” – Licensed Nurses, Medical Doctors, Scientists & Engineers Assist In Helping To Win Your Case
Handicap Facility – Se Habla Español